SPECIAL REPORT
MOST SHARED
- Europe May Be Unprepared for Greece Exit: Official
- Marc Faber: 100% Chance of Global Recession
- How Boaz Weinstein and Hedge Funds Outsmarted JPMorgan
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Where Large Banks Fail, Regionals are Succeeding: Bove
- China Market Lookahead: Stocks Set for More Weakness
- Carly Fiorina: An Open Letter to Mark Zuckerberg
- Are Investors Running Out of Safe Havens to Put Money?
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Weinstein, Hedge Funds Outsmarted JPMorgan
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
There's No ME in aMYlin
 |
CNBC.com |
] is quoting me in a letter to shareholders. AMLN is engaged in an escalating proxy fight with billionaire activist investor Carl Icahn and another big investment firm, Eastbourne. The challengers want to install their own people on the Board of Directors and to presumably sell the company.
Amylin says maintaining the status quo and staying the course is the way to go. And the letter Kliff was telling me about is just the latest salvo.
As the May 27th shareholder meeting and the vote get closer the rhetoric is heating up.
For example, in the new letter Amylin says (all in caps and boldface type), "DO NOT BE MISLED BY ICAHN AND EASTBOURNE. THEIR ONLY PLAN IS TO SELL THE COMPANY AT THE WRONG TIME.". By the way, I think it's worth noting that AMLN put "at the wrong time" in there.
Anyway, while on the one hand I guess I'm flattered, on the other I'm a bit uncomfortable. I'm a reporter. I just cover the story. I don't want to become part of it. Ever.
I want to make absolutely clear to anyone who might try to misinterpret the use of my name in the SEC filing that the quote does not reflect my opinion of Amylin or Byetta or its prospects as a once-a-week injection for diabetes. It was lifted from my on-air CNBC coverage last week of the company's filing for FDA approval of once-a-week Byetta. Amylin is partners with Eli Lilly [LLY
Loading...
()
] and Alkermes [ALKS
Loading...
()
] on the product.
If you read the quote you'll notice that I source the projections for once-a-week Byetta's sales potential to analysts. It is not my analysis or my opinion. In journalism it's called attribution.
Interestingly, in a subsequent press release issued Monday morning about the new SEC filing containing the letter to shareholders there's now a supporting quote, in addition to mine, from an actual analyst.
I certainly don't object to being quoted. After all, that's what I do...quote people. I simply don't want Amylin's use of my quote to be misconstrued by anyone that it in any way means I'm taking sides here. I am not. I would never.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
